BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 34850006)

  • 1. Continuous Glucose Monitoring and HbA1c in Cystic Fibrosis: Clinical Correlations and Implications for CFRD Diagnosis.
    Scully KJ; Sherwood JS; Martin K; Ruazol M; Marchetti P; Larkin M; Zheng H; Sawicki GS; Uluer A; Neuringer I; Yonker LM; Sicilian L; Wexler DJ; Putman MS
    J Clin Endocrinol Metab; 2022 Mar; 107(4):e1444-e1454. PubMed ID: 34850006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous glucose monitoring and advanced glycation endproducts for prediction of clinical outcomes and development of cystic fibrosis-related diabetes in adults with CF.
    Scully KJ; Brenner L; Martin K; Ruazol M; Sawicki GS; Uluer A; Neuringer I; Yonker LM; Sicilian L; Putman MS
    Front Endocrinol (Lausanne); 2024; 15():1293709. PubMed ID: 38379863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemoglobin A
    Chan CL; Hope E; Thurston J; Vigers T; Pyle L; Zeitler PS; Nadeau KJ
    Diabetes Care; 2018 Jul; 41(7):1406-1413. PubMed ID: 29674323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral glucose tolerance test and continuous glucose monitoring to assess diabetes development in cystic fibrosis patients.
    Clemente León M; Bilbao Gassó L; Moreno-Galdó A; Campos Martorrell A; Gartner Tizzano S; Yeste Fernández D; Carrascosa Lezcano A
    Endocrinol Diabetes Nutr (Engl Ed); 2018 Jan; 65(1):45-51. PubMed ID: 29137964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycemia in adults with cystic fibrosis.
    Scully KJ; Marchetti P; Sawicki GS; Uluer A; Cernadas M; Cagnina RE; Kennedy JC; Putman MS
    J Cyst Fibros; 2022 Mar; 21(2):258-263. PubMed ID: 34531155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of hemoglobin A1c to identify dysglycemia in cystic fibrosis.
    Darukhanavala A; Van Dessel F; Ho J; Hansen M; Kremer T; Alfego D
    PLoS One; 2021; 16(4):e0250036. PubMed ID: 33882078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Relationship Between Continuous Glucose Monitoring and OGTT in Youth and Young Adults With Cystic Fibrosis.
    Chan CL; Pyle L; Vigers T; Zeitler PS; Nadeau KJ
    J Clin Endocrinol Metab; 2022 Jan; 107(2):e548-e560. PubMed ID: 34537845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MARKEDLY DELAYED INSULIN SECRETION AND A HIGH RATE OF UNDETECTED OVERT DIABETES CHARACTERIZE GLUCOSE METABOLISM IN ADULT PATIENTS WITH CYSTIC FIBROSIS AFTER LUNG TRANSPLANTATION.
    Winhofer Y; Wolf P; Fellinger P; Tura A; Hillebrand P; Staufer K; Trauner M; Jaksch P; Muraközy G; Kautzky-Willer A; Pacini G; Krebs M; Luger A; Kazemi-Shirazi L
    Endocr Pract; 2019 Mar; 25(3):254-262. PubMed ID: 30913015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous glucose monitoring versus self-monitoring of blood glucose in the management of cystic fibrosis related diabetes: A systematic review and meta-analysis.
    Kumar S; Soldatos G; Ranasinha S; Teede H; Pallin M
    J Cyst Fibros; 2023 Jan; 22(1):39-49. PubMed ID: 35906171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucose >200 mg/dL during Continuous Glucose Monitoring Identifies Adult Patients at Risk for Development of Cystic Fibrosis Related Diabetes.
    Taylor-Cousar JL; Janssen JS; Wilson A; Clair CG; Pickard KM; Jones MC; Brayshaw SJ; Chacon CS; Barboa CM; Sontag MK; Accurso FJ; Nichols DP; Saavedra MT; Nick JA
    J Diabetes Res; 2016; 2016():1527932. PubMed ID: 27999822
    [No Abstract]   [Full Text] [Related]  

  • 11. Abnormal glucose tolerance in a pediatric cystic fibrosis cohort: Trends in clinical outcomes and associated factors in the preceding years.
    Nguyen CQT; Denis MH; Chagnon M; Rabasa-Lhoret R; Mailhot G
    Nutr Metab Cardiovasc Dis; 2021 Jan; 31(1):277-285. PubMed ID: 32981797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in cystic fibrosis-related diabetes: Current status and future directions.
    Lurquin F; Buysschaert M; Preumont V
    Diabetes Metab Syndr; 2023 Nov; 17(11):102899. PubMed ID: 37939435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can continuous glucose monitoring predict cystic fibrosis-related diabetes and worse clinical outcome?
    Zorron M; Marson FAL; Morcillo AM; Gonçalves AC; El Beck MS; Ribeiro JD; Ribeiro AF
    J Bras Pneumol; 2022; 48(2):e20210307. PubMed ID: 35475864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for cystic fibrosis-related diabetes and prediabetes: Evaluating 1,5-anhydroglucitol, fructosamine, glycated albumin, and hemoglobin A1c.
    Tommerdahl KL; Brinton JT; Vigers T; Nadeau KJ; Zeitler PS; Chan CL
    Pediatr Diabetes; 2019 Dec; 20(8):1080-1086. PubMed ID: 31469470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cystic fibrosis-related diabetes: an update on pathophysiology, diagnosis, and treatment.
    Alves C; Della-Manna T; Albuquerque CTM
    J Pediatr Endocrinol Metab; 2020 Jul; 33(7):835-843. PubMed ID: 32651985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Real-time Continuous Glucose Monitoring With Glycemic Control and Acute Metabolic Events Among Patients With Insulin-Treated Diabetes.
    Karter AJ; Parker MM; Moffet HH; Gilliam LK; Dlott R
    JAMA; 2021 Jun; 325(22):2273-2284. PubMed ID: 34077502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycemic indices at night measured by CGM are predictive for a lower pulmonary function in adults but not in children with cystic fibrosis.
    Declercq D; Helleputte S; Marchand S; Van Aken S; Van Braeckel E; Van Daele S; T'Sjoen G; Van Biervliet S; Lapauw B
    J Cyst Fibros; 2023 Jan; 22(1):59-65. PubMed ID: 36068119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous glucose monitoring indices predict poor FEV
    Pallin M; Kumar S; Daley C; Dawadi S; Leong P; Carr E; Soldatos G
    J Cyst Fibros; 2021 Sep; 20(5):785-791. PubMed ID: 33781701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycated Hemoglobin as a First-line Screening Test for Cystic Fibrosis‒Related Diabetes and Impaired Glucose Tolerance in Children With Cystic Fibrosis: A Validation Study.
    Racine F; Shohoudi A; Boudreau V; Nguyen CQT; Denis MH; Desjardins K; Reynaud Q; Rabasa-Lhoret R; Mailhot G
    Can J Diabetes; 2021 Dec; 45(8):768-774. PubMed ID: 33926819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HbA1c as a screening tool for cystic fibrosis related diabetes.
    Burgess JC; Bridges N; Banya W; Gyi KM; Hodson ME; Bilton D; Simmonds NJ
    J Cyst Fibros; 2016 Mar; 15(2):251-7. PubMed ID: 25869326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.